CRISPR Therapeutics (NASDAQ:CRSP) PT Raised to $89.00

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective raised by analysts at Citigroup from $88.00 to $89.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective would suggest a potential upside of 61.67% from the stock’s current price.

Several other research analysts have also recently commented on CRSP. TheStreet upgraded shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. Morgan Stanley increased their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research note on Monday, February 26th. Chardan Capital increased their price target on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Royal Bank of Canada increased their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research note on Thursday, February 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, April 11th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $76.29.

CRISPR Therapeutics Trading Down 2.0 %

Shares of CRSP opened at $55.05 on Thursday. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10. The firm has a fifty day simple moving average of $73.26 and a 200 day simple moving average of $63.29. The stock has a market capitalization of $4.67 billion, a price-to-earnings ratio of -28.09 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. During the same quarter in the previous year, the company posted ($1.41) EPS. The business’s revenue for the quarter was up 3253.3% compared to the same quarter last year. As a group, research analysts predict that CRISPR Therapeutics will post -6.24 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the sale, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Raju Prasad sold 3,524 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the transaction, the chief financial officer now directly owns 6,476 shares in the company, valued at $470,740.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 133,992 shares of company stock worth $9,157,835. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the business. Westside Investment Management Inc. increased its holdings in CRISPR Therapeutics by 4.7% in the 1st quarter. Westside Investment Management Inc. now owns 7,393 shares of the company’s stock valued at $504,000 after buying an additional 332 shares during the period. SeaCrest Wealth Management LLC bought a new position in CRISPR Therapeutics in the 1st quarter valued at about $229,000. InTrack Investment Management Inc bought a new position in CRISPR Therapeutics in the 1st quarter valued at about $522,000. Allspring Global Investments Holdings LLC increased its holdings in CRISPR Therapeutics by 113.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 78,924 shares of the company’s stock valued at $5,379,000 after buying an additional 41,903 shares during the period. Finally, Mirador Capital Partners LP bought a new position in CRISPR Therapeutics in the 1st quarter valued at about $203,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.